This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Background Cardiogenic shock (CS) induced by severe aorticstenosis (AS) is a life-threatening condition with high mortality. Despite advancements in emergency interventions, the optimal treatment approach remains uncertain. Methods A systematic literature review and meta-analysis was performed.
Data shows, versus surgery, the Evolut transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve performance and durable clinical outcomes. Reardon, M.D., Evolut TAVR vs. 9.3%
Among patients with asymptomatic severe aorticstenosis, early TAVR was superior to clinical surveillance in reducing the incidence of death, stroke, or unplanned hospitalization for cardiovascular causes.
Background A quarter of patients with severe aorticstenosis (AS) were asymptomatic, and only a third of them survived at the end of 4 years. Only a select subset of these patients was recommended for aortic valve replacement (AVR) by the current American College of Cardiology/American Heart Association guidelines.
The NOTION trial, a pioneering study, sought to compare the long-term clinical and bioprosthesis outcomes of Transcatheter Aortic Valve Implantation (TAVI) versus Surgical Aortic Valve Replacement (SAVR) in patients with severe aortic valve stenosis (AS) at lower surgical risk. Severe SVD was defined by specific criteria.
The EARLY TAVR trial results demonstrate that early transcatheter aortic valve implantation in patients with asymptomatic severe aorticstenosis is superior to clinical surveillance in significantly reducing the composite primary outcome of death, stroke, or unplanned hospitalization for cardiovascular causes.
each year, according to the American Heart Association 2025 Heart Disease and Stroke Statistical Update. AS occurs when the aortic valve narrows, restricting blood flow from the heart to the body. Learn more about hart valve disease, aorticstenosis and the American Heart Association's educational initatives at heart.org.
Transcatheter aortic valve implantation (TAVI) was superior to surgical aortic valve replacement for reducing death, stroke or rehospitalization in women with severe aorticstenosis, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.
Getty Images milla1cf Mon, 01/29/2024 - 14:24 January 29, 2024 — Despite national guidelines recommending surgical aortic valve replacement (SAVR) for patients under age 65 with severe aorticstenosis , many hospitals are still opting for a nonsurgical approach in patients under 60—possibly with poorer survival rates.
Getty Images milla1cf Wed, 05/15/2024 - 19:10 May 15, 2024 — A new study demonstrated parity between a minimally invasive procedure to replace the aortic valve in the heart— transcatheter aortic valve replacement (TAVR)—and surgical aortic valve replacement (SAVR). 1.11, p=0.70) with similar long-term mortality risks.
A review in The Lancet finds that 20% of the world population carries a genetic risk factor for cardiovascular diseases such as heart attacks, strokes, and aortic valve stenosis: Increased levels of a lipid particle called lipoprotein(a). It is the most common genetic cause of cardiovascular diseases.
BACKGROUND:Current guidelines recommend surgical aortic valve replacement (SAVR) for patients with severe aorticstenosis and unfavorable iliofemoral access. Circulation: Cardiovascular Interventions, Ahead of Print. At 1-year follow-up, there were no significant differences between groups in the primary outcome rates (SAVR, 19.7%
Objective To evaluate whether transcatheter or surgical aortic valve replacement (TAVR or SAVR) affects clinical and haemodynamic outcomes in symptomatic patients with moderately-severe aorticstenosis (AS). <aortic valve area (AVA)<1.5 <aortic valve area (AVA)<1.5 cm 2 , 3.0<peak cm 2 , 3.0<peak
The goal of the PROTECTED TAVR trial was to evaluate the efficacy of intraprocedural cerebral embolic protection (CEP) in reducing strokes among patients undergoing transfemoral TAVR for aorticstenosis.
BackgroundLp(a) (lipoprotein(a)) is an independent risk factor for calcific aortic valve stenosis (CAVS). Journal of the American Heart Association, Ahead of Print. Whether patients with CAVS and high Lp(a) levels are at higher risk of valvular or cardiovascular events is unknown.
Stroke, Volume 56, Issue Suppl_1 , Page AWP205-AWP205, February 1, 2025. Background:The bovine aortic arch is a vascular variant in which the left common carotid artery originates from the brachiocephalic trunk rather than directly from the aortic arch. N=16, 36.4%; p=0.030). vs. 70.0% [50.0-95.0]; 95.0]; p=0.030)(Figure 3).Conclusions:The
Patients with severe aorticstenosis who were treated with either TAVR or surgery had comparable rates of all-cause mortality or disabling stroke at five years, according to research presented during a Late-Breaking Clinical Trial session at ACC.25 25 in Chicago and simultaneously published in JACC.
Objective The optimal medical therapy after surgical aortic valve replacement (SAVR) for aorticstenosis remains unknown. Methods All patients undergoing SAVR due to aorticstenosis in Sweden 2006–2020 and surviving 6 months after surgery were included.
Stroke, Volume 56, Issue Suppl_1 , Page ATP293-ATP293, February 1, 2025. The study was designed to investigate whether aortic arch types (AAT) was associated with the lateralization of subclavian artery stenosis (SAS).Methods:In vs 2.4%, p < 0.001) and (any degree stenosis: 8.4% vs 2.9%, p < 0.001).
Objective To investigate the impact of prior coronary artery bypass grafting (CABG) and coronary lesion complexity on transcatheter aortic valve replacement (TAVR) outcomes for aorticstenosis. The median CABG SYNTAX score was 16 (interquartile range: 9.0–23), The CABG SYNTAX score did not influence the prognosis after TAVR.
BACKGROUND:Data concerning the outcomes of transcatheter aortic valve replacement in type 0 bicuspid aorticstenosis (AS) are scarce. Poverall=0.099) and all stroke (30 days: 1.0% Ascending aortic diameter was the single predictor of 1-year mortality in type 0 bicuspid patients (hazard ratio, 1.59 [95% CI, 1.03–2.44];P=0.035).
A normal functioning aortic valve has three leaflets, usually referred to as cusps, and is positioned at the end of the left ventricle. An aortic valve replacement is required if someone suffers from Aortic Valve Stenosis or Aortic Valve Insufficiency.
milla1cf Fri, 06/07/2024 - 14:50 June 7, 2024 — Medtronic today announced new data from the CoreValve Evolut Clinical Program , reinforcing the positive performance of the Evolut transcatheter aortic valve replacement (TAVR) System compared to surgical aortic valve replacement (SAVR) and other TAVR valves. Evolut vs. 10.6%
Background:The optimal treatment in patients with severe aorticstenosis (AS) and small aortic annulus (SAA) remains to be determined. There were no differences between groups regarding mortality (TAVR: 1 [1.3%], SAVR: 1 [1.4%], p=1.00) and stroke (TAVR:0, SAVR: 2 [2.7%], p=0.24) at 30 days. Circulation, Ahead of Print.
Transcript of the video: Closure line of aortic valve on M-Mode echocardiogram, is seen as central line, while in bicuspid aortic valve, it is an eccentric closure, nearer to one of the walls of the aorta. This eccentricity of closure of the aortic valve leaflets, can be calculated using what is known as eccentricity index.
TAVR and SAVR are procedures to replace a damaged aortic valve that is not functioning properly. The co-primary safety endpoint was designed to assess whether TAVR was non-inferior to SAVR as indicated by an absolute increase of no more than 1% in the composite rate of death or stroke at one year.
According to the Centers for Disease Control and Prevention (CDC), heart disease and stroke rank as the first and fifth leading causes of death in the nation. About 276,000 patients have undergone a TAVR procedure in the United States.
Seven studies showed that TAVR patients had a similar 1-year stroke risk to SAVR patients (OR 0.92, 95% CI 0.64 Odds ratios (ORs) with 95% confidence intervals (CIs) for each study, employing a random-effects model for data synthesis irrespective of heterogeneity, were utilized as measures of outcomes. to 1.17, p=0.30, I2 3%).
There were no statistically significant differences in terms of stroke, paravalvular leak, mechanical ventilation time, blood transfusion requirements, pacemaker implantation, reexploration for bleeding, conversion, wound infection, or in-hospital stay. This was a retrospective, single-center observational study.
However, its postoperative complications can have a significant effect on long-term patient outcomes. 33 preoperative clinical features and 4 postoperative complications were collected in each group.
ABSTRACT Patients with severe aorticstenosis (AS) may develop heart failure (HF), the presence of which has traditionally been deemed as a final stage in AS progression with poor outcomes. The use of transcatheter aortic valve replacement (TAVR) has become the preferred therapy for most patients with AS and concomitant HF.
In women with symptomatic, severe aorticstenosis (AS), TAVR with the balloon-expandable valve was superior to surgical aortic valve replacement in terms of the composite rate of death, stroke and rehospitalization at one-year follow-up, according to a pooled analysis of patient-level data from RHEIA and PARTNER 3 trials presented at TCT 2024.
Stroke, Volume 55, Issue Suppl_1 , Page ATP257-ATP257, February 1, 2024. Background and purpose:The aortic complicated lesion (ACL) is a notable embolic source of cryptogenic stroke (CS) observed in 10-60 % of patients. 3.80, p=0.011) were independently, and past history of stroke (OR 0.35, 95%CI 0.14-0.90,
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. IntroductionIntracranial atherosclerotic disease (ICAD) induces the luminal narrowing of an intracranial vessel and represents one of the major causes of ischemic strokes [1, 2, 3, 4].
Patients with bicuspid aortic valves (BAV) are predisposed to the development of aorticstenosis. We performed a pairwise meta-analysis, comparing the efficacy of transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in patients with BAV. to 4.58, p=0.04). to 4.58, p=0.04).
Stroke, Volume 56, Issue Suppl_1 , Page ATMP12-ATMP12, February 1, 2025. Aorticstenosis (AS) is an age-related valve disease that is associated with a high rate of MACE.
These are true innovators who propose novel approaches to major research challenges in the areas of heart disease, stroke and brain health. Blood lipids such as cholesterol and triglycerides are causal risk factors for coronary heart disease as well as several other types of cardiovascular disease , such as aorticstenosis).
Abstract: Transcatheter aortic valve replacement (TAVR) is an interventional procedure performed in patients with severe aorticstenosis and often required perioperative antiplatelet therapy. Most previous studies have focused on antiplatelet therapy following TAVR.
A cost-effectiveness analysis demonstrates the positive economic value of transcatheter aortic valve replacement (TAVR) using Evolut TAVR compared to surgical aortic valve replacement (SAVR) for low-risk patients. In this contemporary analysis, all-cause mortality or disabling stroke rates at four years were 10.7%
Background: Atrial fibrillation (AF) is common in patients undergoing transcatheter aortic valve replacement (TAVR) and is associated with increased risk of bleeding and stroke. Conclusions: Concomitant WATCHMAN LAAO and TAVR is noninferior to TAVR with medical therapy in severe aorticstenosis patients with AF.
24 will focus on the following three current guideline updates: American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines 2023 Atrial Fibrillation Guideline - Pharmacology II: Strokes vs. Bleeds, What Do the Guidelines Tell Us About Practical Management in A-fib? The Guidelines Sessions at ACC.24
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. Stenosis of the external carotid artery in such patients can be a source of atheroembolism or hypoperfusion. Magnetic resonance imaging revealed embolic appearing strokes in the right middle cerebral artery territory (Figure 1A).
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content